DIA, Chicago 2017

Posted:

June 2017

Richmond Pharmacology is a frequent contributor and recognised thought leader for various scientific meetings worldwide.See below for updated list of upcoming events.

DIA (the Drug Information Association), 2017 18 - 22 June, 2017 | Chicago, USARichmond Pharmacology’s Principal Investigators Dr Taubel and Dr Lorch will be presenting at DIA 2017,ChicagoJoin our CEO Dr Jorg Taubel, who will be presenting on the topic ‘Combined Adaptive Early Phase Trials: From First-Time-in-Human to Proof of Concept in One Protocol’ Tuesday AM – 20th of June.Dr Ulrike Lorch will also be in attendance presenting ‘Combined Adaptive Early Phase Trials: From First-Time-in-Human to Proof of Concept in One Protocol’ her presentation will also take place Tuesday AM –20th June.For more information visit: DIA-2017

Back to news

More about us Adaptive Phase I, II & III Bridging Studies TQT Studies Patient Recruitment

Meet the experts

Richmond Pharmacology has a team of experts with extensive knowledge of clinical research trials.

Latest Publications

View our latest peer-reviewed publications from a selection of our clinical trials.

Latest Videos

Learn more about Richmond Pharmacology by viewing some of our videos.

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021

Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.

View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021

Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses.

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021

J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021

Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.